Monographs for Immediate Release Solid Oral Dosage Forms: Ciprofloxacin Hydrochloride

M.E. OLIVERA; MANZO RH; G.L. AMIDON; H.E. JUNGINGER; K.K. MIDHA; V.P. SHAH; S. STAVCHANSKY; J.B. DRESSMAN; D.M. BARENDS.

JOHN WILEY & SONS INC

Año: 2010 p. 22 - 22

iterature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing ciprofloxacin hydrochloride as the only active pharmaceutical ingredient (API) are reviewed. Ciprofloxacin hydrochloride?s solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Solubility and BA data indicate that ciprofloxacin hydrochloride is a BCS Class IV drug. Therefore, a biowaiver based approval of ciprofloxacin hydrochloride containing IR solid oral dosage forms cannot be recommended for either new multisource drug products or for major scale-up and postapproval changes (variations) to existing drug products.